Z-WEHD-FMK: Irreversible Caspase-5 Inhibitor for Inflammation & Apoptosis Research

Executive Summary: Z-WEHD-FMK is a potent, cell-permeable, irreversible caspase inhibitor that specifically targets caspase-1, caspase-4, and caspase-5, key mediators of inflammation and pyroptosis (Padia et al., 2025). The compound irreversibly blocks caspase-mediated proteolytic cleavage, impeding downstream inflammatory and apoptotic signaling. Z-WEHD-FMK is widely used to dissect caspase signaling in cellular models of infectious disease and inflammation. The product is supplied by APExBIO in a highly pure, research-ready format (product page). Its application in Chlamydia trachomatis-infected HeLa cells at 80 μM for 9 hours robustly inhibits Golgi fragmentation and pathogen proliferation (Padia et al., 2025).

Biological Rationale

Caspases are cysteine proteases that orchestrate programmed cell death and inflammation. Caspase-1, -4, and -5 are classified as inflammatory caspases. Caspase-1 is central to canonical inflammasome-mediated pyroptosis, cleaving gasdermin D (GSDMD) to induce membrane pore formation and cell lysis (Padia et al., 2025). Non-canonical pyroptosis is mediated by direct activation of caspase-4 and -5 upon sensing cytosolic lipopolysaccharide (LPS), leading to GSDMD cleavage and inflammation. Overactivation of these pathways contributes to autoinflammatory and infectious diseases. Research tools that enable selective inhibition of these caspases are essential for dissecting the molecular basis of cell death and inflammatory signaling (internal: golgi-mturquoise2.com). Z-WEHD-FMK (Z-Trp-Glu(OMe)-His-Asp(OMe)-FMK) is designed to fill this critical need.

Mechanism of Action of Z-WEHD-FMK

Z-WEHD-FMK is a peptide-fluoromethyl ketone (FMK) derivative. The FMK group forms a covalent, irreversible bond with the catalytic cysteine residue in the active site of target caspases. This halts caspase-mediated proteolytic cleavage, irreversibly blocking enzyme activity until protein turnover. Z-WEHD-FMK is cell-permeable: it efficiently crosses the plasma membrane to access intracellular caspases. Specificity for caspase-1, -4, and -5 is achieved through the WEHD peptide motif, which mimics endogenous substrate recognition sequences. The compound does not inhibit executioner caspases (e.g., caspase-3, -7, -9) at recommended concentrations, supporting selective pathway interrogation (internal: rilonaceptshop.com). Z-WEHD-FMK's mechanism enables precise, reproducible inhibition of inflammatory caspase activity in cellular and infectious disease models.

Evidence & Benchmarks

• Z-WEHD-FMK irreversibly inhibits human caspase-1, -4, and -5 enzyme activity in vitro and in human cell lysates (Padia et al., 2025, Fig. 3).
• Z-WEHD-FMK treatment at 80 μM for 9 hours prevents Chlamydia-induced fragmentation of the Golgi apparatus in HeLa cells, blocking cleavage of golgin-84 and reducing bacterial proliferation (Padia et al., 2025, Methods).
• The inhibitor is insoluble in water, but dissolves at ≥26.32 mg/mL in ethanol (with ultrasound) and ≥46.33 mg/mL in DMSO, maintaining activity when stored at -20°C (APExBIO product page).
• Z-WEHD-FMK does not inhibit canonical executioner caspases (e.g., caspase-3, -7) at standard experimental concentrations, preserving cell viability in non-inflammatory contexts (internal: z-wehd-fmk.com).
• Use of Z-WEHD-FMK in NSCLC models implicates caspase-1 inhibition in the prevention of pyroptotic cell death, illustrating its value in tumorigenesis studies (Padia et al., 2025).

Applications, Limits & Misconceptions

Z-WEHD-FMK is validated for:

• Inflammation research targeting caspase-1, -4, and -5 pathways.
• Apoptosis and pyroptosis assays in cell biology and infectious disease models.
• Dissecting Chlamydia trachomatis pathogenesis via inhibition of golgin-84 cleavage and Golgi fragmentation.
• Studies of inflammasome activation and cell death mechanisms where selective caspase inhibition is required.

Compared to other scenario-driven reviews, this article provides updated, structured evidence on Z-WEHD-FMK's selectivity, solubility, and experimental benchmark conditions.

Common Pitfalls or Misconceptions

• Z-WEHD-FMK is not water-soluble; improper dissolution leads to precipitation and reduced activity.
• The inhibitor does not block executioner caspases (e.g., caspase-3, -7, -9) and is not suitable for studies requiring pan-caspase inhibition.
• Long-term storage of Z-WEHD-FMK solutions (>1 week) at room temperature leads to loss of activity; always store aliquots at -20°C.
• Z-WEHD-FMK is for research use only and not validated for clinical or diagnostic applications.
• Maximum cellular efficacy requires cell-permeability; use in cell-free or in vivo systems must be validated independently.

Workflow Integration & Parameters

Z-WEHD-FMK integrates seamlessly into cell-based and biochemical assays investigating inflammatory caspases. The recommended protocol for Chlamydia trachomatis-infected HeLa cells is an 80 μM treatment for 9 hours, followed by assessment of Golgi fragmentation and bacterial load (Padia et al., 2025). The compound should be dissolved in DMSO or ethanol (final solvent concentration in culture medium ≤0.5%) and added directly to culture media. For optimal results, use freshly prepared solutions and avoid light exposure. APExBIO provides comprehensive usage guidelines and batch-specific certificates of analysis (Z-WEHD-FMK product page). For broader protocol support and troubleshooting, see this workflow guide, which this article extends by offering updated caspase selectivity data and solubility parameters.

Conclusion & Outlook

Z-WEHD-FMK is a validated, high-specificity reagent for irreversible inhibition of inflammatory caspases in cell biology and infectious disease research. Its robust performance enables reproducible interrogation of apoptosis and pyroptosis pathways, facilitating discovery in inflammation-related diseases and microbial pathogenesis. APExBIO's Z-WEHD-FMK (SKU A1924) remains the standard for selective caspase-1, -4, and -5 inhibition. Future directions include expanded benchmarking in primary cells, organoids, and in vivo models, and the development of next-generation caspase inhibitors targeting non-canonical pyroptosis.